1/52
Looks like no tags are added yet.
Asthma definition
Heterogeneous, chronic inflammatory airway disease with excessive variation in expiratory lung function and respiratory symptoms.
Asthma symptoms
Cough, wheeze, dyspnoea, and chest tightness.
Circadian pattern of lung function in asthma
Worst on waking (and at 2-6 am); best around 12-2 pm.
Alarmins released by airway epithelium
IL-25, IL-33, and TSLP.
Role of IL-4 in asthma
Drives B-cell class switch and memory IgE production.
Role of IL-5 in asthma
Drives eosinophil maturation in bone marrow and recruitment to the lungs.
Role of IL-13 in asthma
Drives mucus production from goblet cells and airway hyperresponsiveness.
Target of Dupilumab
IL-4 receptor alpha (blocks IL-4 and IL-13 signalling).
Target of Mepolizumab
IL-5.
Target of Benralizumab
IL-5 receptor.
Target of Tezepelumab
TSLP (thymic stromal lymphopoietin).
FeNO (fraction of exhaled nitric oxide)
An indicator of the level of Th2 (eosinophilic) airway inflammation.
FeNO threshold for Th2-high asthma
Greater than 27 ppb.
Airway remodelling changes
Subepithelial fibrosis, smooth muscle hyperplasia/hypertrophy, goblet cell hyperplasia, and increased blood vessels.
Reversible airflow limitation (spirometry)
FEV1 increases by ≥200 mL AND ≥12% after bronchodilator.
Four criteria for assessing asthma control
Daytime symptoms, activity limitation, night/waking symptoms, and reliever use.
Good asthma control thresholds
Daytime symptoms ≤2 days/week, no activity limitations/night symptoms, and reliever ≤2 days/week.
Step up vs. Step down timing
Step up if poor control; step down if stable and controlled for 2-3 months.
Adult Level 1 Recommended Track
Budesonide-formoterol (low dose) as needed (AIR).
AIR vs. MART
AIR is PRN only; MART is regular maintenance plus PRN using the same inhaler.
Beta-agonists used as MART
Only formoterol-containing combinations (budesonide-formoterol or beclometasone-formoterol).
Formoterol duration of action
Approximately 12 hours (fast-acting like salbutamol, but long-lasting).
Budesonide-formoterol DPI 200/6 AIR limits
Max 6 puffs at once, 8 per day, 12 in one day temporarily.
Budesonide-formoterol pMDI 100/3 AIR limits
Max 12 puffs at once, 16 per day, 24 in one day temporarily.
Fostair (beclometasone-formoterol) MART limit
Maximum of 8 inhalations total per day.
Children 6-11 Level 2 treatment
Low-dose ICS maintenance + salbutamol PRN.
Why AIR is not recommended for children
AIR trials were only conducted in adults and adolescents.
Only ICS recommended for ages 1-5
Fluticasone propionate.
Why LABAs are never used alone in asthma
Using LABAs without an ICS increases the risk of asthma-related death.
M3 receptor role in airways
Causes airway smooth muscle contraction via Gq and increased calcium.
Beta2 receptor role in airways
Causes airway smooth muscle relaxation via Gs, cAMP, and PKA.
SABA overuse thresholds and risks
≥3 canisters/year = exacerbation risk; ≥12 canisters/year = death risk.
Tiotropium Respimat PBS criteria
Severe asthma uncontrolled on ICS-LABA with ≥1 severe exacerbation in past year.
Triple therapy (ICS/LABA/LAMA) criteria
Age 18+, ≥1 severe exacerbation requiring OCS despite optimised ICS-LABA.
ICS mechanism of trans-activation
GR complex binds GRE to up-regulate anti-inflammatory genes.
ICS mechanism of trans-repression
GR complex recruits HDAC2 to inhibit NF-κB, switching off inflammatory genes.
Why smokers have reduced ICS response
Smoking lowers HDAC2 levels, leading to steroid resistance.
Fluticasone furoate (FF) vs. propionate (FP) potency
FF is approximately 5 times more potent than FP.
ICS linear growth effect in children
Average final height difference of ~1.2 cm, mostly in year 1.
OCS dose for exacerbations
0.5-1 mg/kg (max 50 mg) for 3-5 days; no taper needed.
OCS stewardship toxic threshold
Cumulative lifetime dose of 1000 mg prednisolone-equivalent (~4 courses).
Montelukast neuropsychiatric warning
Can cause sleep disturbances, mood disorders, and suicidal ideation.
Severe asthma definition
Uncontrolled despite regular high-dose ICS-LABA, or requires it to prevent loss of control.
Difficult-to-treat vs. Severe refractory asthma
Difficult-to-treat has fixable issues (adherence, technique); refractory does not.
Vocal cord dysfunction (VCD) presentation
Voice change, throat clearing, and a throat-centred wheeze; unresponsive to ICS.
Aspirin-Exacerbated Respiratory Disease (AERD) triad
Asthma, nasal polyps (chronic rhinosinusitis), and aspirin/NSAID hypersensitivity.
AERD pathophysiology
COX inhibition drops protective PGE2, shunting arachidonic acid to produce bronchoconstricting leukotrienes.
Exercise-Induced Bronchoconstriction (EIB) diagnosis
Fall in FEV1 of ≥10% after exercise or osmotic challenge.
EIB osmolar theory
High ventilation evaporates airway water, cell shrinkage triggers leukotriene and histamine release.
EIB thermal theory
Cold air causes vasoconstriction; rewarming causes rebound hyperaemia and airway narrowing.
EIB prevention strategy
Warm up 10-15 min, breathe through nose, and use reliever 15 min before.
Inhaled salbutamol sport limit without TUE
1600 mcg per 24 hours, and maximum 600 mcg in any 8 hours.
Oral/IV glucocorticoids in competitive sport
Prohibited in-competition only; requires a TUE if used within 5-7 days.